Experiment: 6MPP

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
5	2D 1H-15N HSQC	300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
6	2D 1H-15N HSQC	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
17	2D 1H-15N HSQC	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
7	2D 1H-13C HSQC aliphatic	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
22	2D 1H-1H filtered-TOCSY	170 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 170 uM NRAS Q16K, 170 uM Hb2M	100% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
8	2D 1H-13C HSQC	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
1	3D HNCO	300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
2	3D HNCA	300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
3	3D HNCACB	300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
4	3D HN(COCA)CB	300 uM [U-99% 13C; U-99% 15N] MHC-I HLA-A01:01, 300 uM NRAS Q16K, 300 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
16	3D Cmethyl-CmethylHmethyl	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
14	3D N-CmethylHmethyl	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
13	3D N-NHamide	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
12	3D Hmethyl-CmethylHmethyl	180 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 180 uM NRAS Q16K, 180 uM Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
21	3D 1H-13C filtered-NOESY	170 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val MHC-I HLA-A01:01, 170 uM NRAS Q16K, 170 uM Hb2M	100% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
15	3D Caromatic-CmethylHmethyl	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
10	3D Hmethyl-CaroHaro	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
18	3D Cmethyl-CmethylHmethyl	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
19	3D N-CmethylHmethyl	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800
20	3D Hmethyl-CmethylHmethyl	210 uM [U-15N; U-2H]; [U-15N; U-2H; Methyl-1H; Methyl-13C]-Ala, Ile, Leu & Val; [U-13C; U-15N]-Phe & Tyr MHC-I HLA-A01:01, 210 uM [U-15N] NRAS Q16K, 210 uM [U-2H] Hb2M	90% H2O/10% D2O	20 mM	7.2	1 atm	298	Bruker AVANCE III HD 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III HD	800

NMR Refinement
Method	Details	Software
distance geometry	Structure is calculated based on NMR constraints	CS-ROSETTA

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	50000
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
2	refinement	CS-ROSETTA		Shen, Vernon, Baker and Bax
3	chemical shift assignment	Sparky	NMRFAM	Goddard
4	peak picking	Sparky	NMRFAM	Goddard
1	structure calculation	CS-ROSETTA		Shen, Vernon, Baker and Bax

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.

Prepare Data

Validate Data

Deposit Data

Help and Resources

6MPP

HLA-A*01:01 complex with NRAS Q61K peptide by NMR